Circulating osteoprotegerin and asymptomatic carotid atherosclerosis in postmenopausal non diabetic women

Advances in Medical Sciences

Volumn 59, Issue 2, 2014, Pages 293-298

  Albu, Adriana ^a   Bondor, Cosmina I ^a   Crəciun, Alexandra M ^a   Fodor, Daniela ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Asymptomatic carotid plaques; Carotid intima media thickness; Osteoprotegerin

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOPROTEGERIN; TRIACYLGLYCEROL;

ABDOMINAL CIRCUMFERENCE; ADULT; AGED; ARTERIAL WALL THICKNESS; ARTICLE; ASYMPTOMATIC DISEASE; BODY MASS; CARDIAC PATIENT; CARDIOVASCULAR RISK; CAROTID ARTERY; CAROTID ATHEROSCLEROSIS; COMPARATIVE STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; ECHOCARDIOGRAPHY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MEDICAL EXAMINATION; MEDICAL HISTORY; MENOPAUSE; OBESITY; POSTMENOPAUSE; SMOKING; SYSTOLIC BLOOD PRESSURE;

EID: 84908462575     PISSN: 18961126     EISSN: 18984002     Source Type: Journal    
DOI: 10.1016/j.advms.2014.08.002     Document Type: Article

References (48)

1. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 2004;95:1046-57.
2. Giachelli CM. Ectopic calcification. New concepts in cellular regulation. Z Kardiol 2001;3:31-7.
3. Collin-Osdoby P, Rothe L, Anderson F, Nelson M, Maloney W, Osdoby P, et al. Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem 2001;276:20659-72.
4. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001;142:5050-5.
5. Kiechl S, Werner P, Knoflach M, Furtner M, Willeit J, Schett G. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. Expert Rev Cardiovasc Ther 2006;4:801-11.
6. Bennett BJ, Scatena M, Kirk EA, Rattazzi M, Varon RM, Averill M, et al. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice. Arterioscler Thromb Vasc Biol 2006;26: 2117-24.
7. Venuraju SM, Yerramasu A, Corder R, Lahiri A. Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol 2010;55:2049-61.
8. Abedin M, Omland T, Ueland T, Khera A, Aukrust P, Murphy SA, et al. Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol 2007;99:513-8.
9. Omland T, Drazner MH, Ueland T, Abedin M, Murphy SA, Aukrust P, et al. Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function. Hypertension 2007;49:1392-8.
10. O'Sullivan EP, Ashley DT, Davenport C, Kelly J, Devlin N, Crowley R, et al. Osteoprotegerin is higher in peripheral arterial disease regardless of glycaemic status. Thromb Res 2010;126(6):e423-7.
11. Fuernau G, Zaehringer S, Eitel I, de Waha S, Droppa M, Desch S, et al. Osteoprotegerin in ST-elevation myocardial infarction: prognostic impact and association with markers of myocardial damage by magnetic resonance imaging. Int J Cardiol 2013;167(5):2134-9.
12. Jensen JK, Ueland T, Atar D, Gullestad L, Mickley H, Aukrust P, et al. Osteoprotegerin concentrations and prognosis in acute ischemic stroke. J Intern Med 2010;267(4):410-7.
13. Leuzzi C, Marzullo R, Modena MG. [Is menopause a risk factor for ischemic heart disease in women?]. G Ital Cardiol (Rome) 2012;13(6):401-6. Italian.
14. Mangge H, Almer G, Truschnig-Wilders M, Schmidt A, Gasser R, Fuchs D. Inflammation, adiponectin, obesity and cardiovascular risk. Curr Med Chem 2010;17(36):4511-20.
15. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
16. Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002;22:549-53.
17. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001;86(2):631-7.
18. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997;96(5):1432-7.
19. Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr 2008;21:93-111.
20. Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004;109:2175-80.
21. Golledge J, McCann M, Mangan S, Lam A, Karan M. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke 2004;35(7):1636-41.
22. Vik A, Mathiesen EB, Johnsen SH, Brox J, Wilsgaard T, Njølstad I, et al. Serum osteoprotegerin, sRANKL and carotid plaque formation and growth in a general population - the Tromsø study. J Thromb Haemost 2010;8:898-905.
23. Sutton-Tyrrell K, Lassila HC, Meilahn E, Bunker C, Matthews KA, Kuller LH. Carotid atherosclerosis in premenopausal and postmenopausal women and its association with risk factors measured after menopause. Stroke 1998;29:1116-21.
24. Li R, Duncan BB, Metcalf PA, Crouse 3rd JR, Sharrett AR, Tyroler HA, et al. B-mode-detected carotid artery plaque in a general population. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Stroke 1994;25:2377-83.
25. Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med 1993;328(23):1676-85.
26. Schoenborn CA, Adams PF. Health behaviors of adults: United States, 2005-2007. National Center for Health Statistics. Vital Health Stat 2010;10(245). Appendix II: 79-81.
27. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26(11):3160-7.
28. Grant EG, Benson CB, Moneta GL, Alexandrov AV, Baker JD, Bluth EI, et al. Carotid artery stenosis: grayscale and Doppler ultrasound diagnosis - Society of Radiologists in Ultrasound consensus conference. Ultrasound Q 2003;19(4):190-8.
29. Kastelein JJ, de Groot E. Ultrasound imaging techniques for the evaluation of cardiovascular therapies. Eur Heart J 2008;29(7):849-58.
30. Erdogan B, Aslan E, Bagis T, Gokcel A, Erkanli S, Bavbek M, et al. Intima-media thickness of the carotid arteries is related to serum osteoprotegerin levels in healthy postmenopausal women. Neurol Res 2004;26(6):658-61.
31. Akinci B, Demir T, Celtik A, Baris M, Yener S, Ozcan MA, et al. Serum osteoprotegerin is associated with carotid intima media thickness in women with previous gestational diabetes. Diabetes Res Clin Pract 2008;82(2):172-8.
32. Vik A, Mathiesen EB, Brox J, Wilsgaard T, Njølstad I, Jørgensen L, et al. Relation between serum osteoprotegerin and carotid intima media thickness in a general population - the Tromsø Study. J Thromb Haemost 2010;8:2133-9.
33. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12:1260-8.
34. Pennisi P, Russo E, Gaudio A, Veca R, D'Amico F, Mangiafico RA, et al. The association between carotid or femoral atherosclerosis and low bone mass in postmenopausal women referred for osteoporosis screening. Does osteoprotegerin play a role. Maturitas 2010;67:358-62.
35. Zhou W, Chai HC. Carotid and femoral plaques are distinct entities. J Am Coll Surg 2009;209:S139.
36. Holecki M, Zahorska-Markiewicz B, Janowska J, Mizia-Stec K, Zak-Golab A, Olszanecka-Glinianowicz M, et al. Osteoprotegerin - does it play a protective role in the pathogenesis of bone loss in obese perimenopausal women? Endokrynol Pol 2007;58(1):7-10.
37. Lieb W, Gona P, Larson MG, Massaro JM, Lipinska I, Keaney Jr J, et al. Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality. Arterioscler Thromb Vasc Biol 2010;30:1849-54.
38. Mezquita-Raya P, de la Higuera M, Garcia DF, Alonso G, Ruiz-Requena ME, de Dios Luna J, et al. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. Osteoporos Int 2005;16:1368-74.
39. Blázquez-Medela AM, García-Ortiz L, Gómez-Marcos MA, Recio-Rodriguez JI, Sánchez-Rodríguez A, López-Novoa JM, et al. Osteoprotegerin is associated with cardiovascular risk in hypertension and/or diabetes. Eur J Clin Invest 2012;42(5):548-56.
40. Gannage-Yared MH, Yaghi C, Habre B, Khalife S, Noun R, Germanos-Haddad M, et al. Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: results from both cross-sectional and interventional study. Eur J Endocrinol 2008;158:353-9.
41. Ugur-Altun B, Altun A, Gerenli M, Tugrul A. The relationship between insulin resistance assessed by HOMA-IR and serum osteoprotegerin levels in obesity. Diabetes Res Clin Pract 2005;68:217-22.
42. Golledge J, Leicht AS, Crowther RG, Glanville S, Clancy P, Sangla KS, et al. Determinants of endothelial function in a cohort of patients with peripheral artery disease. Cardiology 2008;111:51-6.
43. Ben-Tal Cohen E, Hohensinner PJ, Kaun C, Maurer G, Huber K, Wojta J. Statins decrease TNF-alpha-induced osteoprotegerin production by endothelial cells and smooth muscle cells in vitro. Biochem Pharmacol 2007;73(1):77-83.
44. Zhang J, Fu M, Myles D, Zhu X, Du J, Cao X, et al. PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Lett 2002;521(1-3):180-4.
45. Dhore CR, Cleutjens JPM, Lutgens E, Cleutjens KBJM, Geusens PPM, Kitslaar PJEHM, et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001;21(12):1998-2003.
46. Ovchinnikova O, Gylfe A, Bailey L, Nordstrom A, Rudling M, Jung C, et al. Osteoprotegerin promotes fibrous cap formation in atherosclerotic lesions of ApoE-deficient mice-brief report. Arterioscler Thromb Vasc Biol 2009;29(10):1478-80.
47. Caidahl K, Ueland T, Aukrust P. Osteoprotegerin: a biomarker with many faces. Arterioscler Thromb Vasc Biol 2010;30:1684-6.
48. Morony S, Tintut Y, Zhang Z, Cattley RC, Van G, Dwyer D, et al. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation 2008;117:411-20.